Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines Agreement provides patients with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strength, from 2025 onwards Accelerates potential for development of a novel flu-COVID-19 combination product based on authorized vaccines with demonstrated efficacy and tolerability, potentially offering patients enhanced convenience and protection Paris and Gaithersburg, Md., United States.

赛诺菲（Sanofi）和诺瓦克斯（Novavax）宣布共同独家许可协议，共同商业化新型新型新型新型流感-新型冠状病毒（flu-COVID-19）联合疫苗。该协议为患者提供了更广泛的途径，通过联合商业力量，从2025年起，加速了基于授权疫苗开发新型流感-新型冠状病毒（flu-COVID-19）联合疫苗的潜力，该疫苗具有明显的功效和耐受性，可能为患者提供更大的便利和保护。美国马里兰州巴黎和盖瑟斯堡（Gaithersburg）。

May 10, 2024. As part of Sanofi’s commitment to developing a diverse portfolio of best-in-class vaccines, the company has entered into a co-exclusive licensing agreement with Novavax, a biotechnology company headquartered in Maryland, US. The terms of the agreement include: a co-exclusive license to co-commercialize Novavax’s current stand-alone adjuvanted COVID-19 vaccine worldwide (except in countries with existing Advance Purchase Agreements and in India, Japan, and South Korea where Novavax has existing partnership agreements); a sole license to Novavax’s adjuvanted COVID-19 vaccine for use in combination with Sanofi’s flu vaccines; and a non-exclusive license to use the Matrix-M adjuvant in vaccine products.

2024年5月10日。作为赛诺菲致力于开发一流疫苗多样化组合的一部分，该公司已与总部位于美国马里兰州的生物技术公司Novax签订了共同独家许可协议。该协议的条款包括：在全球范围内共同商业化Novax目前的独立佐剂新型冠状病毒19疫苗的共同独家许可（除了在有现有预购协议的国家以及Novax有现有合作协议的印度、日本和韩国）；Novavax佐剂COVID-19疫苗与赛诺菲流感疫苗联合使用的唯一许可证；以及在疫苗产品中使用Matrix-M佐剂的非排他性许可。

In addition, Sanofi will take a minority (<5%) equity investment in Novavax. Jean-Francois ToussaintGlobal Head of Vaccines R&D“With flu and COVID-19 hospital admission rates now closely mirroring each other, we have an opportunity to develop non-mRNA flu-COVID-19 combination vaccines offering patients both enhanced convenience and protection against two serious respiratory viruses.

此外，赛诺菲将对Novavax进行少数（<5%）股权投资。Jean-Francois Toussaint全球疫苗研发负责人“流感和新型冠状病毒的住院率现在密切相关，我们有机会开发非mRNA流感-新型冠状病毒-19联合疫苗，为患者提供更大的便利和对两种严重呼吸道病毒的保护。

We’re excited by the prospect of combining Novavax’s adjuvanted COVID-19 vaccine that has shown high efficacy an.

我们对将Novavax的佐剂COVID-19疫苗结合起来的前景感到兴奋，该疫苗已显示出高效性。